VEGFA and renal cell carcinoma: Furthermore, new treatment options, including antiangiogenic drugs targeting Vascular Endothelial Growth Factor and its receptors, Mechanistic Target of Rapamycin inhibitors and an immune checkpoint inhibitor, have improved prognosis in patients with metastatic RCC [17].